AMBU A/SAA

AMBU A/S

101.3DKKD
−0.8−0.78%
At close at May 28, 14:59 GMT
DKK
No trades
See on Supercharts

AMBU_B fundamentals

Key facts

Market capitalization‪26.88 B‬DKK
Founded1956
Employees (FY)‪5.2 K‬
CEOBritt Meelby Jensen
Websiteambu.com
About

Ambu A/S engages in the development, production, and marketing of diagnostic and life-supporting devices for hospitals and rescue services. It operates through the following segments: Anaesthesia; Patient Monitoring & Diagnostics; and Visualisation. The Anaesthesia segment offers products from resuscitators, face masks, and laryngeal masks to the single use flexible intubation scope. The Patient Monitoring & Diagnostics segmet provides electrodes for cardiology, neurophysiology, and polysomnography. The Visualisation segment includes single-use visualisation devices, which are used in single lung ventilation procedure, or a bedside bronchoscopy procedure in the intensive care unit . The company was founded by Holger Hesse in 1937 and is headquartered in Ballerup, Denmark.

Ownership
‪‪232.07 M‬‬
Free Float shares
‪‪140.70 M‬‬ (60.63%)
Closely held shares
‪‪91.36 M‬‬ (39.37%)
Free Float shares
‪‪140.70 M‬‬ (60.63%)
Closely held shares
‪‪91.36 M‬‬ (39.37%)
Capital structure
Market cap
‪‪26.88 B‬‬
Debt
‪‪554.00 M‬‬
Cash & equivalents
‪‪640.00 M‬‬
Enterprise value
‪‪26.79 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪26.88 B‬‬
Price to earning ratio (P/E)
73.51x
Price to sales ratio (P/S)
4.66x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
73.51x
Price to sales ratio (P/S)
4.66x
Valuation ratios
‪0.00‬
‪1.70‬
‪3.40‬
‪5.10‬
‪6.80‬
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪0.00‬
‪40.00‬
‪80.00‬
‪120.00‬
‪160.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−14%‬
‪−7%‬
‪0%‬
‪7%‬
‪14%‬
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪‪−600.00 M‬‬
‪0.00‬
‪‪600.00 M‬‬
‪‪1.20 B‬‬
‪‪1.80 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪400.00 M‬‬
‪‪800.00 M‬‬
‪‪1.20 B‬‬
‪‪1.60 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪400.00 M‬‬
‪‪800.00 M‬‬
‪‪1.20 B‬‬
‪‪1.60 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Endoscopy Solutions
Anaesthesia
Patient Monitoring
By country
Period: 2024
United States
Europe
Rest of World
North America
Denmark

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q3 '24
Q4 '24
Q1 '25
Q2 '25
Q3 '25
‪0.00‬
‪‪400.00 M‬‬
‪‪800.00 M‬‬
‪‪1.20 B‬‬
‪‪1.60 B‬‬
Actual
Estimate
Earnings
Next:Aug 22, 2025
Q3 '24
Q4 '24
Q1 '25
Q2 '25
Q3 '25
‪−0.80‬
‪−0.40‬
‪0.00‬
‪0.40‬
‪0.80‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
27.36%
Earnings retained
Payout ratio (TTM)
Dividend yield TTM
0.38%
Last payment
0.38
Last ex-date
Dec 5, 2024
Last pay date
Dec 9, 2024
Dividend history
‪0.00%‬
‪0.08%‬
‪0.16%‬
‪0.24%‬
‪0.32%‬
2020
2021
2022
2023
2024
‪0.00‬
‪0.10‬
‪0.20‬
‪0.30‬
‪0.40‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪0.00‬
‪‪160.00 M‬‬
‪‪320.00 M‬‬
‪‪480.00 M‬‬
‪‪640.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪1.20 B‬‬
‪‪2.40 B‬‬
‪‪3.60 B‬‬
‪‪4.80 B‬‬
Assets
Liabilities